Diabetic retinopathy is a devastating complication of diabetes, characterized by progressive damage to the microvascular network that nourishes the light-sensitive tissue at the back of the eye. For decades, clinicians have focused their attention on the blood vessels themselves, treating the leaky capillaries and abnormal new vessel growth with laser therapy, injections of anti-VEGF drugs, or surgery. But a growing body of evidence points to a quieter culprit: chronic neuroinflammation, driven in large part by microglia, the resident immune cells of the retina. When these cells become chronically activated in a high-glucose environment, they release a cocktail of pro-inflammatory cytokines that erode the structural and functional integrity of the retinal vasculature from the outside in.

The research team approached the problem with an unusually systematic strategy. Rather than testing piceatannol blindly, they combined network pharmacology with transcriptomic analysis to map the compound’s potential molecular targets against the gene signatures of diabetic retinopathy. The computational screen identified 159 overlapping targets shared between the polyphenol and the disease. Among these, one receptor rose to the top: C-C chemokine receptor type 5, or CCR5, a G protein-coupled receptor best known to immunologists for its role in directing immune cell traffic and, famously, as an entry co-receptor exploited by HIV.

Molecular docking studies predicted that piceatannol could bind directly to CCR5, and the researchers went on to validate that binding affinity experimentally. This mattered because the receptor’s ligand, the chemokine CCL5, was significantly upregulated in the diabetic retina. The picture that emerged was of a signaling cascade, CCL5 binding to CCR5 and triggering the pro-inflammatory transcription factor NF-κB, that could potentially be intercepted at its receptor by a dietary polyphenol. Single-cell and expression analyses added a crucial layer of specificity: CCR5 was found to be expressed predominantly in retinal microglia, placing the immune cells squarely at the center of the pathway.

To test the compound’s effects, the team built disease models at two scales. In the laboratory, they exposed microglia to high glucose concentrations to mimic the diabetic metabolic environment. In living animals, they induced diabetes in mice using streptozotocin, a chemical that destroys insulin-producing cells and produces sustained hyperglycemia. The results in the animals were striking. Mice treated with piceatannol showed restored retinal thickness, reduced formation of acellular capillaries, the ghost vessels that mark dead capillary segments in diabetic retinas, and attenuated vascular leakage, the pathological seepage of fluid and proteins that ultimately destroys vision.

The cellular mechanism behind these improvements centered on microglial polarization. Microglia, like their peripheral cousins the macrophages, can adopt broadly two functional states. The M1 phenotype is pro-inflammatory, unleashing tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6, along with inducible nitric oxide synthase, all of which batter neighboring tissue. The M2 phenotype is restorative, promoting tissue repair through markers such as arginase-1, interleukin-10 and transforming growth factor beta 1. In the diabetic retina, the balance tips decisively toward M1. Piceatannol treatment, the researchers found, inhibited microglial activation and M1 polarization, reduced the secretion of pro-inflammatory cytokines, and promoted the expression of M2-associated markers, all through modulation of the CCL5/CCR5/NF-κB signaling pathway.

The downstream consequences for blood vessels were equally telling. In vitro experiments using human retinal endothelial cells showed that when high glucose pushed co-cultured microglia into their inflammatory state, the endothelial cells suffered: the tight junction proteins zonula occludens-1 and Claudin-5, which zip adjacent endothelial cells together to form the inner blood-retinal barrier, were degraded. Piceatannol suppressed the high-glucose-induced M1 polarization of the microglia and, as a result, preserved the expression of these tight junction proteins. In other words, the compound’s vascular protection appears to be indirect, mediated through the immune cells rather than through a direct effect on the endothelium itself.

The team then put the CCR5 hypothesis to a rigorous causal test. Using small interfering RNA to knock down CCR5 expression, and separately employing pharmacological activation of the receptor, they confirmed that CCR5 sits at the center of the protective mechanism. When the receptor was silenced, piceatannol’s benefits were diminished or recapitulated by the knockdown itself; when the pathway was artificially activated, the compound’s protective effects were counteracted. This pattern of gain- and loss-of-function evidence strengthens the argument that the CCL5/CCR5/NF-κB axis is not merely correlated with the disease process but is functionally required for the drug’s action.

The significance of the work lies partly in its translational framing. Piceatannol is a naturally occurring stilbenoid, meaning it is already present in the human food supply and has been studied for anti-inflammatory and vascular-protective properties in other contexts. Demonstrating a concrete, mechanistically defined role in diabetic retinopathy raises the possibility of repurposing a well-characterized molecule for a condition that currently affects tens of millions of people worldwide. The network pharmacology approach also offers a template for how natural products with dozens of potential targets can be systematically triaged, using docking, transcriptomics and weighted gene co-expression network analysis to converge on the handful of targets that actually matter.

Substantial caveats remain before patients should expect a piceatannol-based therapy. The findings come from cell culture and streptozotocin-induced mouse models, which reproduce key features of diabetic retinopathy but do not capture the full complexity of human disease, which unfolds over decades of metabolic stress. Questions about bioavailability, dosing, retinal drug delivery and long-term safety in a diabetic population remain open, and the study was funded by Chinese national and municipal science programs without reported involvement of commercial drug development. Still, by pinpointing a druggable receptor on retinal microglia and showing that a food-derived polyphenol can restrain the inflammatory cascade that dismantles the blood-retinal barrier, the study adds a compelling new chapter to the growing recognition that diabetic blindness is as much an immunological disease as a vascular one.

Subject of Research: The role of piceatannol in modulating microglial polarization via the CCL5/CCR5/NF-κB axis to protect retinal endothelial cells in diabetic retinopathy

Article Title: Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis

Article References: Tu, Y., Guo, Y., Zhang, Y., Sun, H., Zhu, X., Shen, G., Gu, Y., Xie, L., Song, E., & Zhu, M. (2026). Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08893-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08893-6

Keywords: diabetic retinopathy, piceatannol, microglial polarization, CCR5, CCL5, NF-κB, retinal endothelial cells, blood-retinal barrier, neuroinflammation, tight junctions, network pharmacology, resveratrol

The enzyme at the center of the study, adenosine deaminase acting on RNA 1, or ADAR1, is one of the principal architects of the human transcriptome. It catalyzes the conversion of adenosine to inosine, a process known as A-to-I editing, in double-stranded RNA regions. Because cellular machinery reads inosine as guanosine, this editing can recode messenger RNA transcripts, alter RNA structures, and influence how RNAs are processed, translated or degraded. ADAR1 also plays a well-documented role in innate immunity, where it marks endogenous double-stranded RNA as self and prevents spurious activation of antiviral sensors. In cancer, elevated ADAR1 activity has been linked to tumor progression and immune evasion in several contexts, but its precise contribution to how bladder cancer evades immunotherapy had remained unclear until now.

Using a combination of whole transcriptome sequencing, whole genome sequencing, immunohistochemistry, and patient-derived materials, the team, led by corresponding authors Haiwei Yang, Qiang Lu and Xiao Yang, established that targeting ADAR1 in bladder cancer cells fundamentally reshapes the immune landscape of the tumor microenvironment. When ADAR1 was disabled in experimental models, two critical changes occurred. First, tumors became infiltrated by significantly more CD8-positive T cells, the cytotoxic soldiers of the adaptive immune system that are responsible for directly killing cancer cells. Second, tumor cells increased their expression of PD-L1, the checkpoint ligand through which cancers normally suppress T cell activity. That second change might at first seem counterproductive, but it is precisely what makes the tumors vulnerable to PD-1 blockade: a tumor expressing high levels of PD-L1 but crowded with CD8-positive T cells becomes an ideal target for checkpoint inhibitors, which release the molecular brakes on the waiting immune cells.

To dissect the mechanism, the researchers engineered a mutant form of ADAR1, designated ADAR1-E912A, that is defective in its RNA editing catalytic activity. Comparing cells carrying this editing-defective mutant with cells carrying wild-type ADAR1 allowed them to separate the consequences of the enzyme’s editing function from its other activities. The editing-defective mutant preserved the ability to promote CD8-positive T cell infiltration, and the team traced this effect to the chemokine CCL5, a signaling molecule known to recruit T cells to sites of inflammation and malignancy. Cells expressing the editing-defective mutant produced and secreted more CCL5, creating a chemotactic gradient that drew cytotoxic T lymphocytes into the tumor.

The molecular explanation for the increased CCL5 proved to be a matter of RNA stability. ADAR1 normally edits the messenger RNA encoding CCL5, and these edited transcripts are recognized by endonuclease V, an enzyme that cleaves inosine-containing RNA and thereby destines it for degradation. When ADAR1’s editing function was lost, CCL5 mRNA escaped this editing-dependent degradation pathway, remained stable for longer, and accumulated to higher levels within the cell. The result was a larger pool of CCL5 available for translation and secretion. In effect, ADAR1 acts as a post-transcriptional throttle on one of the most important T cell recruitment signals in the tumor, and switching off that throttle allows the tumor to summon the very immune cells it had been keeping at bay.

The second mechanism the team uncovered concerns PD-L1, the protein through which tumors engage the PD-1 checkpoint on T cells. The researchers found that ADAR1 cooperates with DICER, the cytoplasmic enzyme that processes microRNA precursors into their mature forms, to facilitate the maturation of a specific microRNA, miR-377-3p. Intriguingly, this cooperation did not require ADAR1’s editing catalytic activity, indicating that the protein performs a scaffolding or partner role in the microRNA biogenesis pathway independent of its enzymatic function. Mature miR-377-3p, in turn, represses the expression of PD-L1. In tumors where ADAR1 is abundant, the resulting PD-L1 suppression helps malignant cells keep a low immunological profile even as they hold cytotoxic T cells outside. When ADAR1 is removed, this repression is lifted, PD-L1 rises to the tumor cell surface, and the tumor becomes, paradoxically, an excellent candidate for PD-1 blockade because it now displays the molecular handle that checkpoint drugs are designed to disengage.

Perhaps the most clinically significant element of the study is the identification of an existing drug that can be repurposed as an ADAR1 inhibitor. Fludarabine, a nucleoside analogue long used as a chemotherapeutic agent in hematologic malignancies, was found to suppress ADAR1 on two fronts simultaneously: it inhibited the enzyme’s editing activity and reduced its expression. This dual suppression reproduced the effects seen with genetic targeting of ADAR1. In experimental systems, fludarabine treatment promoted CD8-positive T cell infiltration into tumors, increased PD-L1 expression on tumor cells, and sensitized bladder cancer to PD-1 blockade therapy in both in vitro and in vivo models. The finding suggests that a drug already approved and widely characterized in the clinic could be combined with checkpoint inhibitors to extend their benefits to bladder cancer patients who currently derive little benefit from immunotherapy.

The strength of the study lies partly in the breadth of its experimental evidence. The team worked across multiple platforms, including engineered bladder cancer cell lines with distinct ADAR1 statuses, co-immunoprecipitation and RNA immunoprecipitation assays to map protein and RNA interactions, immunofluorescence combined with fluorescence in situ hybridization to localize molecular events within cells, and quantitative PCR to quantify transcript changes. In vivo, they employed the N-butyl-N-(4-hydroxybutyl) nitrosamine model, a well-established chemical carcinogenesis system for bladder cancer, alongside co-culture experiments with peripheral blood mononuclear cells and experiments using patient-derived organoids that retain features of the original tumors. This triangulation across cell culture, animal models and human-derived material lends considerable weight to the conclusion that ADAR1 targeting genuinely reprograms the tumor microenvironment rather than merely altering isolated molecular readouts.

The implications extend beyond bladder cancer itself. Cold tumors across many cancer types share the fundamental problem of T cell exclusion, and any mechanism that reliably converts cold tumors into hot ones is of broad interest to the oncology community. If ADAR1 functions as a similar gatekeeper in other malignancies, the combination of an ADAR1 inhibitor with PD-1 blockade could represent a generalizable strategy. At the same time, the work highlights the dual and sometimes opposing roles that a single RNA binding protein can play: one activity, the editing of CCL5 mRNA, suppresses immune recruitment, while another, editing-independent cooperation with DICER, suppresses PD-L1 expression. Disentangling these functions will be important as inhibitors are developed and deployed. Fludarabine itself carries a known toxicity profile, and its dosing and safety when combined with checkpoint inhibitors in solid tumors will require careful clinical evaluation. Nevertheless, by identifying a druggable molecular switch that simultaneously pulls immune cells into the tumor and exposes a checkpoint target on the tumor cell surface, the Nanjing team has provided a persuasive mechanistic blueprint for turning one of immunotherapy’s most resistant solid tumors into a far more vulnerable one.

Subject of Research: Targeting the RNA editing enzyme ADAR1 to reprogram the cold tumor microenvironment of bladder cancer and enhance PD-1 blockade immunotherapy

Article Title: Targeting ADAR1 reprograms cold tumors to hot and enhances immunotherapy in bladder cancer

Article References: Bai, K., Zhuang, J., Yu, H., Lv, J., Chen, Y., Jiang, L., Li, K., Yang, H., Lu, Q., & Yang, X. (2026). Targeting ADAR1 reprograms cold tumors to hot and enhances immunotherapy in bladder cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02778-4

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02778-4

Keywords: ADAR1, bladder cancer, RNA editing, PD-1 blockade, fludarabine, CD8-positive T cells, PD-L1, CCL5, miR-377-3p, cold tumors, tumor microenvironment, cancer immunotherapy